Meanwhile, in the multicenter intergroup randomized placebo-controlled phase III trial E4697, Butterfield et al. investigated the effects of adjuvant GM-CSF and a multi-epitope melanoma peptide-based cancer vaccine on patients with completely resected, high-risk stage III/IV melanoma [196]. Here, CSF2 is linked to melanoma.